Wednesday June 12, 2019 0 comments
FluidForm’s FRESH printing technique, developed in Carnegie Mellon University’s Regenerative Biomaterials and Therapeutics Group, enables 3D printing of bio-inks and other soft materials.
Together, Aleph Objects and FluidForm said they will combine their expertise to offer new bioprinting solutions, with the initial offering coming this summer.
3D bioprinting is already being used in labs to create tissue scaffolds and other complex biological structures.
“We’re still at the very beginning of being able to build real functional tissues with 3D bioprinting,” said FluidForm CTO Adam Feinberg. “Collaborations like the one we are building with LulzBot will help make this a reality faster.”
3D biofabrication technology is revolutionizing applications across a wide spectrum of industries, including pharmaceuticals, regenerative medicine, drug screening, food and other animal products, cell-based biosensors, and testing of cosmetics and other health care goods.
Within the next decade, major pharmaceutical companies will be able to replace some animal testing and non-physiological 2D cell culture systems with clinically-relevant 3D bio-printed human tissues.
FluidForm’s novel platform of Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D printing enables fabrication of soft, biological scaffolds for applications in tissue engineering and regenerative medicine.
“Combining proven expertise in professional 3D printers and hardware with 3D biofabrication technology is going to be an absolute game-changer,” said Grant Flaharty, Aleph Objects CEO and president.
“The market for 3D bioprinters and 3D bioprinted tissues is estimated to grow to $1.9 billion by 2028.”